Latest from Kosh Naran

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Korea Needs To Think Bigger On M&As: KHIDI

A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.

Novel Agents Up For US FDA Approval In 2025

CBER has at least 14 and CDER another 10 novel biologics among the more than 60 candidates with a user fee goal in 2025.

Scrip 100: By The Numbers

Despite experiencing significant drops in pharmaceutical revenues in 2023, Pfizer and AbbVie maintained their top positions, ranking first and second respectively, in the latest Scrip 100.

BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps?

Lilly’s Mounjaro to Pfizer’s Paxlovid, the WuXi group has been part of pharma majors’ sourcing chain. How big is the hole clients are to fill when the proposed BIOSECURE Act comes into effect? Here’s a Scrip infographic using Evaluate Pharma data.